Hit enter to search or ESC to close

Investor Centre
Archive

Investor Resources

Investor presentations

ASX Announcements

2020
2019
2018
2017
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004

Financial reports

2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001

Corporate governance

News

Quarterly Cash Flow Report

Highlights: Dr David Stamler appointed CEO; Geoffrey Kempler continues as Non-Executive Chairman New commercial opportunity for PBT2 with Un

Read More
Dr David Stamler appointed CEO

The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce the appointment of

Read More
Quarterly Cash Flow Report

Highlights: Completion of Phase 1 Clinical Trial; PBT434 found to be safe and well-tolerated; clinically tested doses achieve concentrations

Read More

Receive news from Alterity Therapeutics